Skip to main content
icon for Will CRISPR Therapeutics (CRSP) beat quarterly earnings?
Ingresos·CRSP

Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

icon for Will CRISPR Therapeutics (CRSP) beat quarterly earnings?
Ingresos·CRSP

Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

44% probabilidad
Polymarket
NUEVO
44% probabilidad
Polymarket
NUEVO
As of market creation, CRISPR Therapeutics is estimated to release earnings on May 5, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.26 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.26 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices a 56.5% implied probability against CRISPR Therapeutics (CRSP) beating Q1 2026 earnings consensus of -$1.14 per share loss and $8.39 million in revenue, driven by the company's Q4 2025 earnings miss where EPS came in at -$1.37 versus expected -$1.15, a 19% shortfall amid revenue shortfalls despite Casgevy therapy ramp-up. High R&D expenses and biotech sector volatility continue to pressure margins, overshadowing year-over-year loss improvement and robust 864% revenue growth projection from gene-editing milestones. Analyst price targets average $80 amid overweight ratings, but recent stock dips reflect execution risks; watch the May 11 earnings release for Casgevy sales updates and guidance revisions.

As of market creation, CRISPR Therapeutics is estimated to release earnings on May 5, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.26 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.26 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.

If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$168
Fecha de finalización
5 may 2026
Mercado abierto
Apr 23, 2026, 5:46 PM ET

Fuente de resolución

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, CRISPR Therapeutics is estimated to release earnings on May 5, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.26 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.26 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, CRISPR Therapeutics is estimated to release earnings on May 5, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.26 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.26 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Trader consensus on Polymarket prices a 56.5% implied probability against CRISPR Therapeutics (CRSP) beating Q1 2026 earnings consensus of -$1.14 per share loss and $8.39 million in revenue, driven by the company's Q4 2025 earnings miss where EPS came in at -$1.37 versus expected -$1.15, a 19% shortfall amid revenue shortfalls despite Casgevy therapy ramp-up. High R&D expenses and biotech sector volatility continue to pressure margins, overshadowing year-over-year loss improvement and robust 864% revenue growth projection from gene-editing milestones. Analyst price targets average $80 amid overweight ratings, but recent stock dips reflect execution risks; watch the May 11 earnings release for Casgevy sales updates and guidance revisions.

As of market creation, CRISPR Therapeutics is estimated to release earnings on May 5, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.26 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.26 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.

If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$168
Fecha de finalización
5 may 2026
Mercado abierto
Apr 23, 2026, 5:46 PM ET

Fuente de resolución

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, CRISPR Therapeutics is estimated to release earnings on May 5, 2026. The Street consensus estimate for CRISPR Therapeutics's GAAP EPS for the relevant quarter is $-1.26 as of market creation. This market will resolve to "Yes" if CRISPR Therapeutics reports GAAP EPS greater than $-1.26 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents. If CRISPR Therapeutics releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”. If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Cuidado con los enlaces externos.

Preguntas frecuentes

"Will CRISPR Therapeutics (CRSP) beat quarterly earnings?" es un mercado de predicción en Polymarket donde los operadores compran y venden acciones de "Sí" o "No" según si creen que este evento ocurrirá. La probabilidad actual según la comunidad es 44% para "Yes". Por ejemplo, si "Sí" se cotiza a 44¢, el mercado colectivamente asigna una probabilidad de 44% de que este evento ocurra. Estas probabilidades cambian continuamente a medida que los operadores reaccionan a nuevos desarrollos e información. Las acciones del resultado correcto son canjeables por $1 cada una tras la resolución del mercado.

"Will CRISPR Therapeutics (CRSP) beat quarterly earnings?" es un mercado recién creado en Polymarket, lanzado el Apr 23, 2026. Como mercado nuevo, esta es tu oportunidad de ser uno de los primeros operadores en establecer las probabilidades y las señales de precio iniciales del mercado. También puedes guardar esta página en marcadores para seguir el volumen y la actividad de trading a medida que el mercado gana tracción.

Para operar en "Will CRISPR Therapeutics (CRSP) beat quarterly earnings?", simplemente elige si crees que la respuesta es "Sí" o "No". Cada lado tiene un precio actual que refleja la probabilidad implícita del mercado. Introduce tu cantidad y haz clic en "Operar". Si compras acciones de "Sí" y el resultado se resuelve como "Sí", cada acción paga $1. Si se resuelve como "No", tus acciones de "Sí" pagan $0. También puedes vender tus acciones en cualquier momento antes de la resolución para asegurar ganancias o limitar pérdidas.

La probabilidad actual para "Will CRISPR Therapeutics (CRSP) beat quarterly earnings?" es 44% para "Yes". Esto significa que la comunidad de Polymarket actualmente cree que hay una probabilidad de 44% de que este evento ocurra. Estas probabilidades se actualizan en tiempo real basándose en operaciones reales, proporcionando una señal continuamente actualizada de lo que el mercado espera.

Las reglas de resolución para "Will CRISPR Therapeutics (CRSP) beat quarterly earnings?" definen exactamente qué debe ocurrir para que cada resultado sea declarado ganador, incluyendo las fuentes de datos oficiales utilizadas para determinar el resultado. Puedes revisar los criterios de resolución completos en la sección "Reglas" en esta página sobre los comentarios. Recomendamos leer las reglas cuidadosamente antes de operar, ya que especifican las condiciones exactas, casos especiales y fuentes.